Parliamentary activity

Answering body: Department of Health and Social Care

It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.

The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.

In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.

The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.

The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.

Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.

In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.

Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.

Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.

As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.

Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.

Answering body: Department of Health and Social Care

It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.

The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.

In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.

The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.

The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.

Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.

In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.

Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.

Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.

As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.

Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.

Answering body: Department of Health and Social Care

It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.

The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.

In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.

The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.

The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.

Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.

In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.

Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.

Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.

As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.

Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.

Answering body: Department of Health and Social Care

It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.

The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.

In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.

The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.

The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.

Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.

In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.

Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.

Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.

As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.

Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.

Answering body: Cabinet Office

In its Additional Report, the Infected Blood Inquiry recommended changes to the infection severity bands to give greater recognition for the suffering caused particularly by interferon treatment. The Government agrees that changes are needed and has consulted on a proposal to introduce a new infection severity band, referred to as Level 2B, which would increase people’s financial loss and care compensation awards where relevant, to recognise the short-term side-effects that many people suffer due to interferon treatment.

The Government will publish its response to the consultation, which will set out its final decisions on the compensation scheme, within 12 weeks of the closing date. I therefore hope to update Parliament soon on the changes I intend to make to the compensation scheme as a result of the public consultation.

Answering body: Cabinet Office

The Infected Blood Inquiry recommended that a compensation scheme be set up as soon as possible, and by centrally funding the scheme, the Government has been able quickly allocate the money necessary.

The Government firmly believes that access to redress is fundamental in upholding justice and fairness in our society. People must have avenues to seek recourse when they have been wronged or harmed. We hope the Infected Blood Compensation Scheme provides some closure to those who have been wronged under some of those most devastating circumstances.

Answering body: Department of Health and Social Care

It is crucial we protect the safety of haemophilia care and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.

The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.

This includes peer review of UK comprehensive care centres, which has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.

The final peer review report is expected to be published imminently and once published, will be shared with the NHSE Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to Integrated Care Boards and Trust Boards, emphasising the valuable role of peer review and ask for confirmation of their commitment to review and implement the peer review findings.

The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in, and act upon peer review findings.

Answering body: Department of Health and Social Care

It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.

The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.

In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.

The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.

The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.

Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.

In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.

Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.

Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.

As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.

Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.

Answering body: Cabinet Office

On 30 October, the Government launched a public consultation on proposed changes to the infected blood compensation scheme. The core purpose of this consultation was to gather views on how the Government intends to implement the Infected Blood Inquiry’s recommendations, and responses from the infected blood community were particularly encouraged.

Every response to this consultation is being considered carefully and with the seriousness the issue deserves. The consultation closed on 22 January, and the Government will publish its response within 12 weeks of this closing date.

Answering body: Department of Health and Social Care

Medical research was an important area examined in the inquiry, with it concluding that ‘the value of such research to society is enhanced rather than undermined by undertaking research in an ethical and moral way’.

The Department funds research on health and social care through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health and care.

In January 2026, the NIHR published the attached report, From subject to participant and partner, on its website, summarising the concerns raised in the inquiry report, as well as a summary of the research governance changes since and a synthesis of an in-person workshop. The NIHR and partners who attended the workshop are committed to upholding the highest standards of research governance to drive better inclusivity in the evidence base for care, working with those who use, manage, or work in health and care services to share learning and drive improvement. The NIHR requires all applicants to demonstrate how their research will address existing inequalities in health and social care as a condition of funding.

The NIHR was created in 2006, many decades after individuals received infected blood in the United Kingdom. The NIHR did not therefore fund any clinical trials or research where individuals received infected blood. The NIHR has strong ethical, safety, and legal governance arrangements, including processes to ensure informed consent for those participating in research, and includes parental and guardian consent for children involved in research.

The NIHR funds a wide range of research relevant to the Infected Blood Inquiry. Work includes making blood donation and transfusion safer by improving transfusion practice, reducing variation in practice and ensuring greater resilience and efficiency throughout the blood supply chain.

This includes research on improving the safety of blood transfusions and blood products, and research to improve better detection and treatments for blood borne infections, including through opt out testing in accident and emergency departments for HIV, and Hepatitis B and C.

Answering body: Department of Health and Social Care

Given the long-running nature of the infected blood scandal, not all medical records will still be available, and eligibility for compensation will be determined based on the balance of probabilities.

The Infected Blood Compensation Authority (IBCA) will try to get as much information, including medical records and information about an applicant’s condition, from organisations who already have this information. This should mean those claiming will be asked for the least amount of information possible.

The IBCA will provide assistance to those who believe their medical records have been lost or destroyed. The role of the IBCA’s claim managers includes helping individuals who are claiming to gather information, including medical evidence where available, to support their claim.

In July 2025, the Permanent Secretary of the Cabinet Office wrote to the chairs of the Public Accounts and Public Administration and Constitutional Affairs Committees to set out the measures being taken to prioritise faster payments to victims of the infected blood scandal. One of these measures is to use the powers in the Victims and Prisoners Act to get records from the Infected Blood Inquiry, and using testimony to contribute to the assessment of proof of infection.

Organisations that remove, store, and use human tissue for some types of health research, medical treatment, post-mortem examination, education and training, and for display in public, are independently regulated by the Human Tissue Authority.

Answering body: Cabinet Office

Compensation tariffs for infected and affected people under the Scheme have been informed, but not limited, by current practice in UK courts and tribunals.

The Infected Blood Inquiry Response Expert Group Final Report provides detail on how the Fatal Accidents Act 1976 was considered when developing the tariffs under the Scheme. This can be found here: https://www.gov.uk/government/publications/infected-blood-inquiry-response-expert-group-summary-report/infected-blood-inquiry-response-expert-group-final-report#foreword-by-the-minister-for-the-cabinet-office.

Answering body: Cabinet Office

In line with recommendations of the Infected Blood Inquiry, the Government has publicly consulted on proposed changes to the compensation scheme. The consultation closed on 22nd January, and we will publish our response within 12 weeks of the consultation’s closing date. The Government is keen to prioritise amendments to the compensation scheme as recommended, while continuing to focus on the swift delivery of compensation to all victims of this scandal.

Answering body: Cabinet Office

The Government launched a public consultation on proposed changes to the infected blood compensation scheme on 30 October 2025 that ran for the standard 12 weeks and closed on 22 January. This consultation adhered to the Cabinet Office Consultation Principles and was open to the public, with responses particularly encouraged from those in the infected blood community. The Government is considering each response to the consultation with the seriousness the issue deserves, and will publish its response within 12 weeks of the consultation’s closing date. An Equality Impact Assessment is not required to be carried out for public consultations, but the Government will provide one alongside any legislation arising from the implementation of the consultation’s outcome.

In its Additional Report, the Inquiry recommended that the Government reconsider how the Infected Blood Compensation Scheme provides compensation to those currently receiving Special Category Mechanism (SCM) payments or its equivalents. The Government accepted this recommendation.

The public consultation proposed that anyone currently receiving SCM or equivalent payments through the Infected Blood Support Schemes would be automatically eligible for a Severe Health Condition award. The Government has also consulted on how eligibility should be established for people who are not registered with an Infected Blood Support Scheme (IBSS) but who experience the same impact on their day-to-day life for the same reasons.

The Technical Expert Group (TEG) is convening a series of roundtables with key organisations and charity representatives to discuss aspects of the Infected Blood Inquiry Additional Report recommendations for the compensation scheme, to inform their advice to the Government. This targeted engagement is separate to the Government’s consultation. The TEG held roundtables on 15 and 17 December 2025, which focused on establishing the eligibility criteria for living infected people who are not currently registered with an IBSS, in relation to the award to recognise impacts associated with SCM, and its equivalents. The attendee list was informed by the key representatives in the infected blood community that the Government regularly engages with. To ensure transparency, the minutes of meetings of the TEG are published on GOV.UK. The minutes of these roundtable meetings were published on 29 January 2026.

The TEG invited further written responses from the representatives to supplement the discussion of the roundtables. The TEG therefore received written responses after the initial roundtables on SCM had been held. The TEG have, since then, reviewed these written responses and will be making sure they too are properly reflected in a summary document which will be published on GOV.UK.

Answering body: Cabinet Office

The Government launched a public consultation on proposed changes to the infected blood compensation scheme on 30 October 2025 that ran for the standard 12 weeks and closed on 22 January. This consultation adhered to the Cabinet Office Consultation Principles and was open to the public, with responses particularly encouraged from those in the infected blood community. The Government is considering each response to the consultation with the seriousness the issue deserves, and will publish its response within 12 weeks of the consultation’s closing date. An Equality Impact Assessment is not required to be carried out for public consultations, but the Government will provide one alongside any legislation arising from the implementation of the consultation’s outcome.

In its Additional Report, the Inquiry recommended that the Government reconsider how the Infected Blood Compensation Scheme provides compensation to those currently receiving Special Category Mechanism (SCM) payments or its equivalents. The Government accepted this recommendation.

The public consultation proposed that anyone currently receiving SCM or equivalent payments through the Infected Blood Support Schemes would be automatically eligible for a Severe Health Condition award. The Government has also consulted on how eligibility should be established for people who are not registered with an Infected Blood Support Scheme (IBSS) but who experience the same impact on their day-to-day life for the same reasons.

The Technical Expert Group (TEG) is convening a series of roundtables with key organisations and charity representatives to discuss aspects of the Infected Blood Inquiry Additional Report recommendations for the compensation scheme, to inform their advice to the Government. This targeted engagement is separate to the Government’s consultation. The TEG held roundtables on 15 and 17 December 2025, which focused on establishing the eligibility criteria for living infected people who are not currently registered with an IBSS, in relation to the award to recognise impacts associated with SCM, and its equivalents. The attendee list was informed by the key representatives in the infected blood community that the Government regularly engages with. To ensure transparency, the minutes of meetings of the TEG are published on GOV.UK. The minutes of these roundtable meetings were published on 29 January 2026.

The TEG invited further written responses from the representatives to supplement the discussion of the roundtables. The TEG therefore received written responses after the initial roundtables on SCM had been held. The TEG have, since then, reviewed these written responses and will be making sure they too are properly reflected in a summary document which will be published on GOV.UK.

Answering body: Cabinet Office

The Government launched a public consultation on proposed changes to the infected blood compensation scheme on 30 October 2025 that ran for the standard 12 weeks and closed on 22 January. This consultation adhered to the Cabinet Office Consultation Principles and was open to the public, with responses particularly encouraged from those in the infected blood community. The Government is considering each response to the consultation with the seriousness the issue deserves, and will publish its response within 12 weeks of the consultation’s closing date. An Equality Impact Assessment is not required to be carried out for public consultations, but the Government will provide one alongside any legislation arising from the implementation of the consultation’s outcome.

In its Additional Report, the Inquiry recommended that the Government reconsider how the Infected Blood Compensation Scheme provides compensation to those currently receiving Special Category Mechanism (SCM) payments or its equivalents. The Government accepted this recommendation.

The public consultation proposed that anyone currently receiving SCM or equivalent payments through the Infected Blood Support Schemes would be automatically eligible for a Severe Health Condition award. The Government has also consulted on how eligibility should be established for people who are not registered with an Infected Blood Support Scheme (IBSS) but who experience the same impact on their day-to-day life for the same reasons.

The Technical Expert Group (TEG) is convening a series of roundtables with key organisations and charity representatives to discuss aspects of the Infected Blood Inquiry Additional Report recommendations for the compensation scheme, to inform their advice to the Government. This targeted engagement is separate to the Government’s consultation. The TEG held roundtables on 15 and 17 December 2025, which focused on establishing the eligibility criteria for living infected people who are not currently registered with an IBSS, in relation to the award to recognise impacts associated with SCM, and its equivalents. The attendee list was informed by the key representatives in the infected blood community that the Government regularly engages with. To ensure transparency, the minutes of meetings of the TEG are published on GOV.UK. The minutes of these roundtable meetings were published on 29 January 2026.

The TEG invited further written responses from the representatives to supplement the discussion of the roundtables. The TEG therefore received written responses after the initial roundtables on SCM had been held. The TEG have, since then, reviewed these written responses and will be making sure they too are properly reflected in a summary document which will be published on GOV.UK.

Answering body: Cabinet Office

Given the historic nature of the infected blood scandal, the Government recognises that not all medical records will still be available. The Infected Blood Compensation Scheme has been designed to minimise as far as possible the burden on those applying, and as set out in the Infected Blood Compensation Scheme Regulations 2024, eligibility for the Infected Blood Compensation Scheme will be determined based on the balance of probabilities. The Infected Blood Compensation Authority will provide assistance to those who believe their medical records have been lost or destroyed.

Work has taken place across Government and the Infected Blood Compensation Authority to understand steps that can be taken to reduce as many barriers as possible to support the processing of claims. On 3 July 2025, the Permanent Secretary of the Cabinet Office wrote to the Chairs of the PAC and PACAC Committees to set out the measures being taken to prioritise faster payments to victims of the infected blood scandal. One of these measures is to use the powers in the Victims and Prisoners Act to get records from the Infected Blood Inquiry, and using testimony to contribute to the assessment of proof of infection.

Answering body: Cabinet Office

The Government launched a public consultation on proposed changes to the infected blood compensation scheme on 30 October 2025 that ran for the standard 12 weeks and closed on 22 January. This consultation adhered to the Cabinet Office Consultation Principles and was open to the public, with responses particularly encouraged from those in the infected blood community. The Government is considering each response to the consultation with the seriousness the issue deserves, and will publish its response within 12 weeks of the consultation’s closing date. An Equality Impact Assessment is not required to be carried out for public consultations, but the Government will provide one alongside any legislation arising from the implementation of the consultation’s outcome.

In its Additional Report, the Inquiry recommended that the Government reconsider how the Infected Blood Compensation Scheme provides compensation to those currently receiving Special Category Mechanism (SCM) payments or its equivalents. The Government accepted this recommendation.

The public consultation proposed that anyone currently receiving SCM or equivalent payments through the Infected Blood Support Schemes would be automatically eligible for a Severe Health Condition award. The Government has also consulted on how eligibility should be established for people who are not registered with an Infected Blood Support Scheme (IBSS) but who experience the same impact on their day-to-day life for the same reasons.

The Technical Expert Group (TEG) is convening a series of roundtables with key organisations and charity representatives to discuss aspects of the Infected Blood Inquiry Additional Report recommendations for the compensation scheme, to inform their advice to the Government. This targeted engagement is separate to the Government’s consultation. The TEG held roundtables on 15 and 17 December 2025, which focused on establishing the eligibility criteria for living infected people who are not currently registered with an IBSS, in relation to the award to recognise impacts associated with SCM, and its equivalents. The attendee list was informed by the key representatives in the infected blood community that the Government regularly engages with. To ensure transparency, the minutes of meetings of the TEG are published on GOV.UK. The minutes of these roundtable meetings were published on 29 January 2026.

The TEG invited further written responses from the representatives to supplement the discussion of the roundtables. The TEG therefore received written responses after the initial roundtables on SCM had been held. The TEG have, since then, reviewed these written responses and will be making sure they too are properly reflected in a summary document which will be published on GOV.UK.

Answering body: Cabinet Office

The Government launched a public consultation on proposed changes to the infected blood compensation scheme on 30 October 2025 that ran for the standard 12 weeks and closed on 22 January. This consultation adhered to the Cabinet Office Consultation Principles and was open to the public, with responses particularly encouraged from those in the infected blood community. The Government is considering each response to the consultation with the seriousness the issue deserves, and will publish its response within 12 weeks of the consultation’s closing date. An Equality Impact Assessment is not required to be carried out for public consultations, but the Government will provide one alongside any legislation arising from the implementation of the consultation’s outcome.

In its Additional Report, the Inquiry recommended that the Government reconsider how the Infected Blood Compensation Scheme provides compensation to those currently receiving Special Category Mechanism (SCM) payments or its equivalents. The Government accepted this recommendation.

The public consultation proposed that anyone currently receiving SCM or equivalent payments through the Infected Blood Support Schemes would be automatically eligible for a Severe Health Condition award. The Government has also consulted on how eligibility should be established for people who are not registered with an Infected Blood Support Scheme (IBSS) but who experience the same impact on their day-to-day life for the same reasons.

The Technical Expert Group (TEG) is convening a series of roundtables with key organisations and charity representatives to discuss aspects of the Infected Blood Inquiry Additional Report recommendations for the compensation scheme, to inform their advice to the Government. This targeted engagement is separate to the Government’s consultation. The TEG held roundtables on 15 and 17 December 2025, which focused on establishing the eligibility criteria for living infected people who are not currently registered with an IBSS, in relation to the award to recognise impacts associated with SCM, and its equivalents. The attendee list was informed by the key representatives in the infected blood community that the Government regularly engages with. To ensure transparency, the minutes of meetings of the TEG are published on GOV.UK. The minutes of these roundtable meetings were published on 29 January 2026.

The TEG invited further written responses from the representatives to supplement the discussion of the roundtables. The TEG therefore received written responses after the initial roundtables on SCM had been held. The TEG have, since then, reviewed these written responses and will be making sure they too are properly reflected in a summary document which will be published on GOV.UK.

Answering body: Cabinet Office

The Scheme has been designed to minimise as far as possible the burden on those applying, and as set out in the Infected Blood Compensation Scheme Regulations 2024, eligibility for the Scheme will be determined based on the balance of probabilities. The Infected Blood Compensation Authority will provide assistance to those who believe their medical records have been lost or destroyed.

In addition to this, on 3 July 2025, the Permanent Secretary of the Cabinet Office wrote to the Chairs of the PAC and PACAC Committees to set out the measures being taken to prioritise faster compensation payments, and one of these measures is to use the powers in the Victims and Prisoners Act to get records from the Infected Blood Inquiry, and using testimony to contribute to the assessment of proof of infection.

Answering body: Cabinet Office

As stated in my previous answer to Question 71230, to provide additional background information on each booking would incur disproportionate costs as this information is not centrally held.

Answering body: Cabinet Office

The Infected Blood Inquiry 2024-25 financial report was published on 6 November, the same day that the audited figures were approved for publication. The report can be found here: https://www.infectedbloodinquiry.org.uk/about/financial-reports

Answering body: Cabinet Office

The Chair of the Infected Blood Inquiry has been paid at the level of a High Court judge, except that he has declined any pension as a result of his work for the Inquiry. The Ministry of Justice publishes the judicial salaries each year. The Chair of the Infected Blood Inquiry is currently receiving one tenth of this salary in recompense for his work.

Answering body: Cabinet Office

The Public Office (Accountability) Bill is currently progressing through parliament. The legislation will include a requirement that all public bodies establish a professional duty of candour for staff set out within a wider code of ethics. This obligation will require public bodies to promote the ethical conduct of their employees. The Government will drive forward implementation with determination and hold public sector organisations accountable. Public Sector leaders will join ministers on a dedicated new implementation board to monitor progress.

Public inquiries are independent of Government and can make recommendations of their choosing. Government takes the recommendations of inquiries very seriously, and determines which recommendations it accepts. To ensure clarity and transparency of progress on the recommendations that Government has accepted, we have established a record on GOV.UK of inquiry recommendations, starting with the Grenfell Tower Inquiry and Infected Blood Inquiry. This will be periodically updated and expanded to capture future inquiry recommendations. This will be an enduring mechanism for monitoring and tracking government implementation of inquiry recommendations. It will allow the public to track the progress of implementation enhancing public trust in Government.

Answering body: Cabinet Office

Public inquiries are independent of Government and can make recommendations of their choosing. Government takes the recommendations of inquiries very seriously, and determines which recommendations it accepts. To ensure clarity and transparency of progress on the recommendations that Government has accepted, we have established a record on GOV.UK of inquiry recommendations, starting with the Grenfell Tower Inquiry and Infected Blood Inquiry. This will be periodically updated and expanded to capture future inquiry recommendations. This will be an enduring mechanism for monitoring and tracking government implementation of inquiry recommendations. It will allow the public to track the progress of implementation enhancing public trust in Government.